Hence, IL-1 inhibitors may effectively attenuate bone resorption caused by OSCC infiltration by suppressing the stimulatory effect of IL-1 on tumor-induced and conventional RANKL-induced osteoclastogenesis (Figure 6). This evidence concerns the gene IL1B and neoplasm.